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Abstract
Background: Treating elderly breast cancer patients remains a challenge but the increasing availability of
immunotherapeutic approaches instills optimism that these tumours may also be susceptible to immune control.
Because aging leads to a number of alterations in the immune system (“immunosenescence”) reflecting potential
exhaustion which could compromise immunomodulatory antibody therapy, here we have assessed the
immunocompetence of elderly breast cancer patients compared with a group of younger patients, and related this to
the 5-year survival of the former.
Methods: T-cell responses to Her-2 peptide pools in vitro were assessed by analyzing pro- and anti-inflammatory
cytokine production by CD4+ and CD8+ T-cells in 40 elderly and 35 younger breast cancer patients.
Results: The proportions of older and younger patients whose peripheral T-cells responded to Her-2 peptides in vitro
were found to be similar, although a significantly higher fraction of younger patients possessed IL-2-producing CD4+
Her-2-reactive T-cells than in the elderly (p = 0.03). However, IL-2 production did not impart a survival benefit to the
latter. In contrast, there was a survival benefit of possessing Her-2-reactive CD8+ T-cells, but this was abrogated in
patients if they also had CD4+ Her-2-responsive T-cells that producedIL-5 and/or IL-17 (p = 0.01). This resulted in a 5-yr
survival rate of only 29 % compared to 76 % for patients whose her-2-reactive CD4+ T-cells did not produceIL-5 and/or
IL-17. Additionally, patients whose CD8+ T-cells produced TNF had a significantly better survival than those that did not
(93 % compared to 52 %, p = 0.01), whereas no survival benefit was attributable to possessing IFN-γ-producing cells.
Conclusions: Elderly breast cancer patients appear perfectly immunocompetent to respond to Her-2 peptide pools in
vitro, with response patterns very similar to younger patients. The nature of this response is associated with 5-year
survival of these elderly patients, suggesting that boosting anti-tumor responses and modulating the nature of the T-cell
response is likely to be effective even in potentially immunosenescent elderly breast cancer patients, and might be
useful for predicting which patients are most likely to benefit from such treatments.
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Background
The prevalence of most types of cancer increases with
age. One reason for this may be that aging is associated
with dysregulated immunity, which could contribute to
increased susceptibility to infections and cancer [1].
Treating elderly breast cancer patients remains a major
challenge. The elderly are underrepresented in clinical
trials, of which there are hardly any that have specifically
considered elderly cohorts. Generally, the same treatment
regimens are applied to both younger and older cancer
patients, but the latter are not able to tolerate chemother-
apy or radiotherapy to the same extent and may thus be
under-treated [2, 3]. Although there are many suggestions
as to how to treat elderly breast cancer patients [4-6], and
considering the recent breakthroughs in immunotherapy
of melanoma and other cancer types, more investigations
need to be conducted to understand the immune system
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of these patients and the potential role of ageing and
immunosenescence in treatment outcome. The hallmarks
of immunosenescence may be observed chronologically
earlier in chronic viral infections and cancer [7, 8]. There
is a number of alterations that are known to occur with
aging [9, 10], which include changes in the number and
distribution of T and B lymphocytes and their differenti-
ation states [8, 11]. As T-cells play a crucial role in adaptive
immunity, their efficient activation to defend against cancer
or viral infection is important. Dendritic cells (DCs) are
necessary for activating the T-cells efficiently. Aging may
also result in alterations of important co-receptors on DCs
that could result in weakened T-cell response, possibly
reducing anti-cancer immunity [12, 13]. Generally, higher
levels of serum inflammatory markers are also observed in
the elderly, which could play a role in the activation of
immunosuppressive cell subsets making it more difficult to
resist cancer [14, 15]. Thus, there are several loci at which
immunosenescence could interfere with anti-cancer im-
munity and accordingly compromise immunotherapies.
The recent striking clinical success of employing immuno-
modulatory antibodies such as anti-CTLA-4, PD-1 or PDL-
1which “take the brakes off” immunity and are showing
extremely promising results in some cancers in a propor-
tion of treated patients makes it even more important to
determine the effect of age on the immune status of cancer
patients [16-18]. Such therapies are likely to be effective
only when the patient remains capable of mounting an
anti-cancer immune response. In elderly patients, immuno-
senescence could compromise these responses.
Earlier, we showed that the presence of peripheral T-cells
responding to certain tumor-associated antigens (TAA) in
stage IV melanoma was associated with longer survival and
that the pro- or anti-inflammatory nature of the T cell re-
sponse influenced the strength of this association [19, 20].
Thus, T-cell responsiveness to TAA is an important prog-
nostic biomarker of survival. Melanoma patients tend to be
relatively young compared to most other solid cancer pa-
tients, and so we asked whether this type of biomarker
reflecting T-cell functional integrity would also be inform-
ative in older patients. We therefore elected to examine this
issue in a cohort of some of the oldest such patients,
namely in elderly female breast cancer patients. We had
previously reported that elderly patients with in vitro CD8+
T-cell responses against pooled Her-2 peptides survived
longer than those who did not [21], suggesting that immu-
nosenescence had not compromised responsiveness and
that immunomodulatory therapies should also be effective
in these patients. Here, we compared the immunocompe-
tence of these elderly patients with a group of younger
patients and found that they were indeed similar in this
respect. We have continued these first studies on the
elderly to dissect the nature of their CD4+ and CD8+ T-
cell responses to Her-2 peptides in relation to their overall
survival, where we were able to show the association of
certain pro- and anti-inflammatory cytokines produced by
CD4+ and CD8+ T-cells with overall survival, analogous
to similar findings in melanoma [20].
Results
T-cell responses to Her-2
A majority of the elderly(97 %, n = 38) and all younger
(100 %, n = 35) breast cancer patients analyzed had in vitro
T cell responses to mixtures of Her-2 peptides. FACS plots
from a representative donor are shown in Additional file 1:
Table S2. CD4+ T-cell responses to Her-2 were observed in
most individuals in the case of both older (32/38, 87 %) and
younger (33/35, 94 %) patients, whereas only 18 of the
former (47 %) and 21 of the latter (60 %) possessed CD8+
T-cells responding to Her-2 peptides. ThisCD8+ T-cell
response was present irrespective of whether the patients
also had a CD4+ T-cell response to Her-2. Taking advan-
tage of our ability to analyze 6 different cytokines simultan-
eously by intra-cellular staining of individual T-cells by flow
cytometry, we grouped the Her-2 responders according to
the cytokines produced by their CD4+ and CD8+ T-cells.
CD8+ T-cell responses to Her-2
As described above, a CD8+ T-cell response to Her-2,
defined as the production of any one of the 6 tested
cytokines, was observed in 18/38 (47 %) older and 21/35
(60 %) younger patients. In a high proportion of these
patients, CD8+ T-cells responding to Her-2produced the
pro-inflammatory cytokines TNF (14/18, 78 % in old;
16/21, 76 % in young) and IFN-γ (13/18, 72 % in old;
18/21, 86 % in young).Only a small proportion of CD8+
T-cells produced IL-2 and IL-10 in either old or young
patients (Tables 1 and 2).
CD4+ T-cell responses to Her-2
Analyzing the nature of the CD4+ T-cell responses to Her-
2 peptides, we observed that these cells mainly produced
the pro-inflammatory cytokines TNF (27/32, 84 % in old;
27/33, 82 % in young), IFN-γ (23/32, 72 % in old; 28/33,
85 % in young) and, unlike for CD8+ T-cells, also IL-2 (13/
32, 41 % in old; 22/33, 67 % in young). The higher fraction
of younger relative to older patients whose CD4+ T-cells
produced IL-2 in response to Her-2 was statistically signifi-
cantly different (p = 0.03). As for CD8+ T-cell responses,
IL10, IL-5 and IL-17 were rarely produced by either young
or old patients (Tables 1 and 2).
The T-cell response to Her-2 correlates with overall
survival
Previously, we had shown that elderly patients who had a
CD8+ T-cell response to Her-2 had a survival advantage
over those who did not(p = 0.03). The overall (5-year)
survival rate was 52 % for patients without a CD8+ T-cell
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response to Her-2, compared with 82 % for those had a
CD8+ T-cell response. There was only 17 % mortality in
the group of patients with a CD8+ T-cell response to Her-2
whereas this was 45 % for patients without a CD8+ T-cell
response. In the present study, we stratified patients ac-
cording to whether they had only a CD8+ T-cell response,
only a CD4+ T-cell response or both CD4+ and CD8+ T-
cell responses to Her-2 peptides, and performed a Kaplan-
Meier analysis (Table 3). We confirmed a survival benefit
for patients with Her-2-reactive CD8+ T-cells as observed
in our earlier study, but there was no survival advantage for
patients with a CD4+ T-cell response to Her-2. Moreover,
those patients with a CD8+ T-cell response to Her-2 who
also had a CD4+ T-cell response had poorer survival than
those with only a CD8+ T-cell response. A significant early
negative impact on survival can also be observed for
patients with no CD8+ T-cell response to Her-2 (Gehan
Breslow test: p = 0.02) (Fig. 1). The 5-year survival rate for
patients with a solely CD4+ T-cell response was 49 % com-
pared to 77 % and 100 % for those with combined CD4+
and CD8+ T-cell responses or only a CD8+ T-cell response,
respectively. Survival analyses were not possible in the
younger patients because only two had died. Nonetheless,
these two had both CD4+ and CD8+ T-cell responses to
Her-2.
Impact of the presence of CD4+ T-cells producing IL-5
and IL-17 on survival
Patients were stratified according to the cytokines produced
by their CD4+ or CD8+ T-cells. Considering the elderly
breast cancer patients, Kaplan-Meier survival analysis
showed that patients whose CD4+ T-cells produced IL-5
tended to have poorer outcomes (p = 0.1, Fig. 2a) with a
survival rate of 43 % compared to 73 % for patients whose
CD4+ T-cells did not produce IL-5 when stimulated with
Her-2 peptides. A weaker trend towards a similar impact
on survival was observed for patients whose CD4+ T-cells
produced IL-17 (p = 0.3, Fig. 2b). Here, those whose CD4+
T-cells produced IL-17 had a 33 % 5-year survival com-
pared to 70 % for those who did not produce IL-17. Despite
the lack of statistical significance when considering IL 5
and IL 17 production separately, when we analyzed
patients whose CD4+ T-cells produced IL-5 and/or IL-17,
we did observe a significant impact on the overall survival
Table 1 Cytokines produced by Her-2 responders in old breast cancer patients
Old (n = 38)
CD4 Response No. of patients % Dead 5-year survival rate P value
TNF Yes 27 37 60 0.1
No 11 18 81
IFN-γ Yes 23 43 57 0.1
No 15 13 84
IL-5 Yes 7 57 43 0.1
No 31 23 73
IL-10 Yes 3 33 67 0.8
No 35 31 65
IL-2 Yes 13 46 54 0.3
No 25 24 74
IL-17 Yes 3 67 33 0.3
No 35 29 70
IL-5 and or IL-17 Yes 10 50 29 0.01
No 28 25 76
CD8
TNF Yes 14 7 93 0.01
No 24 46 52
IFN- γ Yes 13 23 76 0.3
No 25 36 62
IL-10 Yes 2 50 50 0.7
No 36 31 68
IL-2 Yes 1 0 100 0.5
No 37 32 66
Results of survival analysis according to Kaplan Meier method and p values from Mantel-Cox (log-rank) test
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(p = 0.01, Fig. 3a) in these elderly breast cancer patients.
Thus, the survival rate for patients whose CD4+ T-cells
produced IL-5 and/or IL-17 was 29 % compared to 76 %
for the patients without these cytokines. From the Kaplan-
Meier analysis of different parameters in the elderly we
observed the expected impact of metastasis on survival
(Additional file 2: Table S1). Limiting the analysis to non-
metastatic elderly breast cancer patients only, we still
observed a similar negative impact on survival for the
patients whose CD4+ T-cells produced IL-5 and/or IL-17
(p = 0.02, Fig. 3b). Here, the survival rate was only 33 %
compared to 80 % for patients whose CD4+ T-cells did
not produce these cytokines.
Analogous observations were also made anecdotally in
the younger patients, where those whose CD4+ T-cells
produced IL-5 had poor survival, with 25 % (2/8) of the
IL-5-producing patients dying, compared to none whose
CD4+ T-cells did not produce IL-5.
Impact of TNF-producing CD8+ T-cells on survival
We previously reported the beneficial effects of having a
CD8+ T-cell response to Her-2. Here, we investigated the
function of these Her-2 specific CD8+ T-cells to identify
the factors associating with survival benefit in this cohort.
We observed that patients whose CD8+ T-cell produced
TNF had a significantly better survival than those whose
CD8+ T-cells did not produce TNF, when all elderly
patients were included in the analysis (p = 0.01, Fig. 4a).
The survival rate for the patients whose CD8+ T-cells pro-
duced TNF was 93 % compared to 52 %, for those with no
Table 2 Cytokines produced by Her-2 responders in young
breast cancer patients
Young (n = 35)
CD4 Response No. of patients % Dead P value
TNF Yes 27 7 0.5
No 8 0
IFN-γ Yes 28 7 0.6
No 7 0
IL-5 Yes 8 25 0.04
No 27 0
IL-10 Yes 4 0 0.7
No 31 6
IL-2 Yes 22 9 0.4
No 13 0
IL-17 Yes 6 17 0.6
No 29 3
IL-5 and or IL-17 Yes 12 17 0.1
No 23 0
CD8
TNF Yes 16 13 0.3
No 19 0
IFN-γ Yes 18 11 0.3
No 17 0
IL-10 Yes 2 0 0.3
No 33 6
IL-2 Yes 2 0 0.8
No 33 6
Results of survival analysis according to Kaplan Meier method and p values
from Mantel-Cox (log-rank) test
Table 3 Phenotype of Her-2 responders in older patients
Response to Her-2 No. of patients Percentage dead p value
CD4 response Yes 33 36 % 0.1
No 4 0 %
CD8 response Yes 18 13 % 0.03
No 19 47 %
CD4 and CD8 response Yes 14 21 % 0.2
No 23 39 %
Results of survival analysis according to Kaplan Meier method and p values from Mantel-Cox (log-rank) test
Fig. 1 Survival analysis of elderly breast cancer patients according to
CD8+ T-cell responses to Her-2peptides in vitro. Survival analysis of
elderly patients (n = 38) grouped according to CD8+ T-cell responses
to Her-2 (CD8 response), CD4+ and CD8+ T-cell responses (CD4 &
CD8response) and CD4+ T-cell responses to Her-2 (CD4 response)
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TNF-producing CD8+ T-cells. This survival advantage was
still observed when only non-metastatic elderly patients
were considered (p = 0.05, Fig. 4b). In the case of non-
metastatic patients, these figures were 92 % and 57 %,
respectively. No survival associations could be observed in
young.
Impact of IFN-γ producing CD8+ T-cell on survival
Here, we grouped the patients according to CD8+ T-
cell production of IFN-γ. Unlike the findings with
TNF above, unexpectedly, Kaplan-Meier survival ana-
lysis indicated no significant differences between IFN-
producers and non-producers both in young and old
(p = 0.3, Fig. 4c).
Discussion
In the present study, we investigated associations of the
presence of circulating Her-2-reactive CD4+ and CD8+ T-
cells with survival in older breast cancer patients relative to
their pro- and anti-inflammatory cytokine production on
stimulation, and compared the immunocompetence of the
elderly, as assessed in this manner, with that of younger
patients. Previously, we had reported a survival benefit ac-
cruing to patients having a CD8+ T-cell response to Her-2
[21]. To test the hypothesis that the immune system in the
elderly may be compromised due to aging, here we investi-
gated differences in T-cell responses to Her-2 in younger
and older breast cancer patients. To the best of our know-
ledge, this is the first study to investigate the phenotype
and function of Her-2 reactive T-cells, or those reactive to
Fig. 2 Survival analysis of elderly breast cancer patients according to
IL-5 or IL-17 production by Her-2-stimulated CD4+ T-cells. a Patients
grouped according to IL-5 production; b IL-17 production
Fig. 3 Survival analysis of elderly breast cancer patients according to IL-5
and/or IL-17 production by Her-2-stimulated CD4+ T-cells. a patients
grouped according to IL-5 and/or IL-17 production in all patients and b
in non-metastatic patients only
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any tumor-associated antigen, in young and old breast can-
cer patients.
In the present study, stratifying the patients according to
those having a CD8+ T-cell response alone (positive impact
on survival as previously shown), or both CD4+ and CD8+
T-cell responses, or only a CD4+ T-cell response revealed a
trend towards a negative general survival impact for CD4+
T-cell reactivity in older patients. These results clearly con-
firmed the importance of having a CD8+ T-cell response to
Her-2 but also showed that there was reduced survival
when a CD4+ T-cell response to Her-2 was also present in
the same patient. This implies that at least in terms of
responses to Her-2, CD4+ T-cell reactivity to this TAA is
likely to have unanticipated negative effects. CD4+ regula-
tory T cells would be the obvious candidates for the cells
mediating these negative effects. The lack of CD8+ T-cell
responses in patients with poorer survival could also be due
to the presence of increased levels of Tregs. This would be
consistent with other reported studies showing that Tregs
could control the T-cell response against certain TAAs in
an antigen-specific manner [22, 23]. We were not able to
test for classic Treg phenotypes in the current study due to
the limitations of the flow cytometric technique, but will
focus on this question in future studies. We can only say at
this juncture that one cytokine commonly implicated in
Treg function, IL-10, does not seem to be responsible for
these results, whereas two other cytokines not generally
implicated in Treg function, namely IL-5 and IL-17, do
seem to play important roles. Thus, functional analysis of 6
different cytokines allowed us to group patients according
to the cytokines produced by the CD4+ and CD8+ T-cells
responding to Her-2. Survival analysis showed that the
presence of CD4+ T-cells producing IL-5 and/or IL-17 had
a negative impact on survival in the elderly (p = 0.01). Com-
pared to other anti-inflammatory cytokines, the role of IL-5
in peripheral cells seems to be under-investigated. Studies
have indicated that IL-5 may facilitate lung metastasis, and
high expression of IL-5 in the tumor was also negatively
associated with survival [24, 25]. A potential role in im-
mune surveillance has been proposed [26]. Similarly, there
are few data on IL-17 in this context. Although IL-17 is
primarily considered a pro-inflammatory cytokine, its role
in cancer is still unclear. Some studies have shown anti-
tumor effects of IL-17, so that it has been proposed for use
as a cancer immunotherapeutic [27, 28]. However, tumor-
infiltrating lymphocytes with a high level of IL-17-positivity
correlate with poor prognosis in some studies [29, 24], and
an association of IL-17 with Tregs in the tumor has been
reported [29]. We also need to bear in mind that not only
Tregs, but also myeloid-derived suppressor cells (MDSCs)
may play a role in suppressing T-cell activity. We previously
reported the possible suppressive role of MDSCs and Tregs
in relation to T-cell responses to Her-2 and also the pos-
sible indirect role of these immunosuppressive subsets in
Fig. 4 Survival analysis of elderly breast cancer patients according to
CD8+ T-cell responses to Her-2 peptides in vitro. a patients grouped
according to TNF production in all patients and b in non-metastatic
patients only; c patients grouped according to IFN-γ production
(all patients)
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breast cancer [21]. MDSCs are also associated with IL-17,
as they are able to mediate IL-17 production by naïve T-
cells, depending on the cytokines produced by the MDSCs
themselves [30]. Consistent with the present report, our
previous study investigating the role of IL-17 in the context
of CD4+ T-cell responses to TAAs documented a negative
impact ofIL-17-producing T-cells in late-stage melanoma
[20]. There are several other cytokines such as IL-4 and IL-
13 that are known to have a negative impact on survival
[31, 32] and which would have been interesting to examine
here, especially as we previously found that IL 4 was rele-
vant in melanoma. IL-13 is known to regulate cancer inva-
sion and metastasis in different cancers [31, 32]. In our
previous study on melanoma, we observed a negative
impact on survival for the patients who produced IL-4
reactive to Melan-A [20]. IL-4 is also known to trigger the
cancer proliferation mechanism [33]. Not only these but
also IL-6 and IL-1 have shown a negative impact on
survival and tumor progression [34, 35]. However, the
number of different variables that could be tested at the
same time was limited and we were unable to include
these other cytokines in the present analysis.
The role of the pro-inflammatory cytokines IL-2, IFN-γ
and TNF in cancer is usually considered to be well-
established. They play an important role in inducing a
protective immune response [36] and IL-2 has long been
used as an immunotherapeutic drug which can result in a
small minority of very durable responses [37]. In the
present study, one of the few differences that we observed
between younger and older patients was that significantly
lower proportion of the latter possessed Her-2-reactive
IL-2 producing CD4+ T-cells, possibly contributing to bet-
ter survival of the former. However, whether or not an
elderly patient possessed IL-2-producing CD4+ T-cells
had no impact on survival.
IFN-γ is known to play an important role in anti-tumor
activity [38, 39] and has also been considered as an immu-
notherapeutic drug to treat cancer patients [40, 41]. In our
study, however, we could discern no significant survival
advantage for patients with Her-2-reactive CD8+ T-cells
producing IFN-γ, although there was a survival advantage
for patients who had Her-2-reactive TNF-producing CD8+
T-cells. TNF is involved in a number of important cellular
functions including cell proliferation, survival and death
and has been used in patients with locally advanced tumors
[42]. In the present study, we observed that patients whose
CD8+ T-cells produced TNF had a significant survival ad-
vantage over those who did not, indicating the importance
of Her-2-reactive TNF-producing CD8+ T-cells for these
elderly breast cancer patients.
Conclusions
From our results, we propose that the nature of the anti-
tumor T-cell response and the TAA targeted by T-cells
present in the circulation is important and has an impact
on patient survival. Considering the results presented in
this study, depletion of Her-2-specific IL-5- and IL-17-
producing CD4+ T-cells and enrichment of TNF-
producing CD8+ T-cells for adoptive T-cell therapy
would be important in breast cancer. Thus, considering
our previous results, it is not only immunosuppressive
cells like Tregs and MDSCs that might have to be targeted
but it is also important to consider the specific cytokines
produced by the CD4+ and CD8+ T-cell that are reactive
to, in this case, Her-2. This study may also provide some
mechanistic insights for a better understanding of the im-
mune system in elderly and younger breast cancer patients.
In any event, the findings that elderly breast cancer patients
are not immunosenescent according to the assays con-
ducted in this work augur well for the efficacy of immuno-
modulatory antibodies even in older patients.
Methods
Patients
The study included 40 elderly and 35 younger patients
with breast cancer (Additional file 3: Figure S1). Blood
samples from patients with different TNM stage were
collected between March and November 2009, at the
University Hospital Tuebingen. Blood was drawn prior
to any treatment or surgery. Standard Ficoll-Hypaque
gradient centrifugation was used to isolate the peripheral
blood mononuclear cells (PBMCs) before they were
cryopreserved for experimental purposes. The study
was approved by the Institutional Ethics Committee of
University Hospital Tuebingen (71/2009BO2) and a
waiver of informed consent was granted for this study.
Detection of tumour-associated antigen-reactiveT-cells
To assess T-cell reactivity to Her-2, a 12-day in vitro culture
was performed as described previously [21]. First, after
thawing carefully, washing extensively, and assessing viabil-
ity, PBMCs (1x106) were cultured in X-Vivo 15 defined
medium (Lonza) supplemented with IL-4 (5 ng/ml: Sandoz,
Basel, Switzerland) and IL-7 (5 ng/ml: Sterling-Winthrop,
US), on day 0. On day 1, the PBMCs were stimulated with
mixtures of Her-2 15-mer overlapping peptides (with an
overlap of 11 amino acids) (PepMix, JPT Technologies,
Berlin, Germany) at a concentration of 1 μg/ml. The cells
were supplemented with IL-2 (40U/ml: Chiron Behring
GmbH, Marburg, Germany) on day3. On day12, after
harvesting and washing, the cultured T-cells were re-
stimulated (0.4-0.5 x 10 6 cells/well) with Her-2 PepMix at
a concentration of 1 μg/ml or left unstimulated as a nega-
tive control for 12 hours. Golgi-plug (BD Biosciences) was
added at 1 μl/ml to all cultures. Patients’ cells were stimu-
lated with influenza nucleoprotein (NP) and membrane
protein (M1) peptides as a positive control, as all subjects
have been exposed to influenza during their lives and all
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possess T cells responsive to these peptides. After harvest-
ing and washing, the cells were incubated with Gamunex
(Talecris) to block Fc receptors, and with ethidium mono-
azide (EMA,MoBiTec GmbH, Goettingen, Germany), a
marker for dead cells. Intracellular cytokine staining was
performed after fixing and permeabilizing the cells with
Cytofix/Cytoperm (BD Biosciences). Cells were simultan-
eously stained with CD3-PO (Invitrogen), CD4-Pacific Blue,
TNF-FITC, IL-2-Alexa Fluor-700, IL-5-PE (Bio Legend),
CD8-APC-Cy7, IFN-γ-PE-Cy7 (BD Biosciences), IL-
10-APC (Miltenyi Biotech) and IL-17-PerCP-Cy5.5
(eBioscience). Following the staining, cells were mea-
sured on a BD-LSR-II flow cytometer using the FACS-
Diva software (BD-Biosciences).
Flow cytometry data analysis
Data were analyzed using FlowJo software (Tree Star Inc.)
as shown earlier [21]. To detect cytokine-producing cells,
the stimulated samples were compared with unstimulated
(negative) control and the response was considered positive
when at least one cytokine was produced by the stimulated
sample (representative FACS plot shown in Additional file
1: Table S2), defined as an at least two-fold increase in the
peptide-stimulated culture compared to the unstimulated
negative control, as established in earlier studies [19, 21].
Statistical analysis
Chi-square testing was performed to compare independ-
ent groups and Kaplan-Meier analysis was performed
(Log-rank test and Gehan-Breslow test) for the survival
estimates. Graph Pad Prism 6 was used to perform this
analysis. A value of p < 0.05 was considered statistically
significant.
Additional files
Additional file 1: Table S2. Kaplan-Meier analysis of clinico-pathological
parameters in older patients. (DOCX 17 kb)
Additional file 2: Table S1. Clinico-pathological characteristics of
younger and older patients. (DOCX 15 kb)
Additional file 3: Figure S1. CD8+ and CD4+ T-cell response to Her-2:
A representative plot of control and Her-2-stimulated cytokine
(eg.TNF-producing CD8+ T-cells and CD4+ T-cells). (PPTX 89 kb)
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